Search Results

Business

OncoResponse Announces Appointment of Carol Gallagher to Board of Directors

OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer Responders, announced the appointment of Carol Gallagher, Pharm.D., as an Independent Director to its Board of Directors.

September 6, 2023

·

2 min read

Drug Development

OncoResponse Announces Initiation of Phase 1/2 Clinical Trial of OR502, anti-LILRB2 Antibody, in Subjects with Advanced Cancer

OncoResponse today announced the dosing of the first participant in the Phase 1/2 trial of OR502, a novel, humanized anti-leukocyte immunoglobulin like receptor B2 (LILRB2) antibody that rescues innate and adaptive immune responses from LILRB2 mediated immune suppression.

November 29, 2023

·

3 min read

BioForest

OncoResponse Awarded $13 Million in Funding from CPRIT and Raises $14 Million in Added Funds from Investors to Advance Cancer Immunotherapy

OncoResponse today announced it has been awarded a $13 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

May 18, 2023

·

3 min read

BioForest

OncoResponse to Present at 41st Annual J.P. Morgan Healthcare Conference

OncoResponse announced that Clifford Stocks, Chief Executive Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 11 a.m. PST.

January 5, 2023

·

1 min read

BioForest

OncoResponse Presents at AACR 2023 Annual Meeting Preclinical Data Highlighting Dual Antagonist Antibodies Targeting both LILRB1 and LILRB2

OncoResponse today presented preclinical data highlighting its identification of dual antagonist antibodies targeting both LILRB1 and LILRB2 as potential anti-cancer immunotherapies at the American Association for Cancer Research Annual Meeting in Orlando, Florida.

April 19, 2023

·

3 min read

BioForest

OncoResponse Announces Presentation of Preclinical Data on Dual Antibodies Targeting LILRB1 and LILRB2 at American Association for Cancer Research Annual Meeting 2023 (AACR 2023)

OncoResponse today announced a poster presentation at the upcoming American Association for Cancer Research Annual Meeting being held April 14-19, 2023, at the Orange County Convention Center in Orlando, Florida.

March 15, 2023

·

2 min read

Drug Development

OncoResponse IDs Elite Cancer Responders’ Antibodies to Make IO More Effective

OncoResponse is developing an innovative cancer therapy based upon antibodies produced by patients to components in the tumor microenvironment that regulate the immune response.

May 9, 2022

·

4 min read

·

Gail Dutton

BioForest

OncoResponse to Present at Upcoming Investor Conferences

OncoResponse today announced that Clifford Stocks, Chief Executive Officer, will participate in two upcoming investor conferences.

November 22, 2021

·

1 min read

BioForest

OncoResponse Announces Clinical Supply Agreement with Regeneron to Evaluate OR2805 in Combination with Libtayo® (cemiplimab) in Patients with Advanced Cancer

OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of elite cancer responders, today announced a clinical supply agreement with Regeneron for PD-1 inhibitor Libtayo® (cemiplimab).

September 7, 2022

·

3 min read

Drug Development

OncoResponse Announces Preclinical Data Highlighting OR2805 Discovery from Elite Responder Platform and OR502 anti-LILRB2 Antibody at SITC 2022

OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Responders, today announced preclinical data on immuno-oncology candidates OR2805 and OR502 presented at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting.

November 11, 2022

·

3 min read